MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

Search

Checkpoint Therapeutics Inc

Gesloten

SectorGezondheidszorg

4.04 0.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.02

Max

4.04

Belangrijke statistieken

By Trading Economics

Werknemers

23

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+31.19% upside

Dividenden

By Dow Jones

Volgende Winsten

9 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

207M

Vorige openingsprijs

3.79

Vorige sluitingsprijs

4.04

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Checkpoint Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2025, 10:23 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 dec 2024, 00:24 UTC

Belangrijke Marktbewegers

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 jul 2024, 13:02 UTC

Belangrijke Marktbewegers

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 mrt 2025, 02:12 UTC

Acquisities, Fusies, Overnames

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mrt 2025, 02:12 UTC

Acquisities, Fusies, Overnames

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mrt 2025, 02:11 UTC

Acquisities, Fusies, Overnames

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mrt 2025, 02:11 UTC

Acquisities, Fusies, Overnames

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mrt 2025, 02:10 UTC

Acquisities, Fusies, Overnames

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mrt 2025, 02:10 UTC

Acquisities, Fusies, Overnames

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mrt 2025, 02:06 UTC

Acquisities, Fusies, Overnames

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Peer Vergelijking

Prijswijziging

Checkpoint Therapeutics Inc Prognose

Koersdoel

By TipRanks

31.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.3Ā USDĀ  31.19%

Hoogste 7Ā USD

Laagste 4.1Ā USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Checkpoint Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

$

Over Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.